InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
EFF
0.00%
$1.31
EVANS & PARTNERS AUSTRALIAN FLAGSHIP FUND - Corporate Spotlight
Currently unlisted.
Proposed listing date: 27 JUNE 2018, 11:00 AM AEST ##
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.